- 全部删除
- 您的购物车当前为空
Anticanceragent 242 (7) 在多种癌细胞线显示出显著的抗癌效果.对于以下癌症细胞具有较低的半抑制浓度 (IC50):A2780 (IC50= 0.24 μM, 卵巢腺癌)、A2780cis (IC50= 0.45 μM, 卵巢腺癌)、CCD18Co (IC50= 0.59 μM, 非恶性人成纤维细胞)、A549 (IC50= 0.32 μM, 肺腺癌)、HT29 (IC50= 0.26 μM, 大肠直肠腺癌) 及 MCF7 (IC50= 0.55 μM, 乳腺腺癌) 等.
Anticanceragent 242 (7) 在多种癌细胞线显示出显著的抗癌效果.对于以下癌症细胞具有较低的半抑制浓度 (IC50):A2780 (IC50= 0.24 μM, 卵巢腺癌)、A2780cis (IC50= 0.45 μM, 卵巢腺癌)、CCD18Co (IC50= 0.59 μM, 非恶性人成纤维细胞)、A549 (IC50= 0.32 μM, 肺腺癌)、HT29 (IC50= 0.26 μM, 大肠直肠腺癌) 及 MCF7 (IC50= 0.55 μM, 乳腺腺癌) 等.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 待询 | 待询 | |
50 mg | 待询 | 待询 |
Anticancer agent 242 相关产品
产品描述 | Anticanceragent 242 (7) exhibits anticancer activity across various cancer cell types. For instance, in ovarian adenocarcinoma cells A2780, it shows an IC50 of 0.24 μM and in A2780cis cells, an IC50 of 0.45 μM. Additionally, it demonstrates efficacy in CCD18Co non-malignant human fibroblasts with an IC50 of 0.59 μM, lung adenocarcinoma A549 cells with an IC50 of 0.32 μM, colorectal adenocarcinoma HT29 cells with an IC50 of 0.26 μM, and in breast adenocarcinoma MCF7 cells with an IC50 of 0.55 μM. |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容